Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.
By P. Flume, B. O’Sullivan, K. Robinson, C. Goss, P. Mogayzel, D. Willey-Courand, J. Bujan, J. Finder, M. Lester, L. Quittell and 5 more. American Journal of Respiratory and Critical Care Medicine, 2007
1,128 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/548068fa55b9e7e8bea83e019aaa77fe8fe2c5f9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Optimal trees for prediction and prescription (2018, background): “, in cystic fibrosis [46] and mental illness [68], and can potentially lead to significant improvements in health outcomes and reduce costs.”
- Estimating Individualized Treatment Rules Using Outcome Weighted Learning (2012, background): “quality recommendations accounting for individual heterogeneity (Sargent et al. 2005; Flume et al. 2007; Insel 2009).”
- New Statistical Learning Methods for Estimating Optimal Dynamic Treatment Regimes (2015, background): “…on (Murphy et al. 2007); the treatment regimen for non-small cell lung cancer involves multiple lines of treatment (Socinski and Stinchcombe 2007); and clinicians routinely update therapy according to the risk of toxicity and antibiotics resistance in treating cystic fibrosis (Flume et al. 2007).”
- The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update (2021, neutral): “Inhaled colistin is another aerosolized antipseudomonal that is an option for chronic infection, with studies demonstrating conflicting results regarding the superiority of tobramycin compared to colistin, and current guidelines do not recommend inhaled colistin [124, 129, 130].”